Calicheamicin-conjugated humanized anti-CD33 mouse monoclonal antibody, CMA-676, has recently been introduced to clinics as a promising drug to treat patients with acute myeloid leukemia (AML) in relapse. However, the mechanism of action of CMA-676 has not been well elucidated. The cytotoxic effect of CMA-676 on HL60, NOMO-1, NB4, NKM-1, K562, Daudi, and the multidrug-resistant sublines, NOMO-1/ADR and NB4/MDR, was investigated by cell cycle distribution and morphology. These studies were done by a video-microscopic system, DNA fragmentation, dye exclusion and 3 H-thymidine uptake after analysis of CD33, CD34, P-glycoprotein (P-gp), multidrug resistance (MDR)-associated protein and lung-related protein on these cells. A dose-dependent, selective cytotoxic effect of CMA-676 was observed in cell lines that expressed CD33, and was dependent on the amount of CD33 and the proliferative speed of the cells. Sensitive cells were temporally arrested at the G2/M phase before undergoing morphological changes. CMA-676 is not effective on P-gp-expressing multidrug-resistant sublines compared with parental cell lines. MDR modifiers, MS209 and PSC833, restored the cytotoxic effect of CMA-676 in P-gp-expressing sublines. CMA-676 is a promising agent in the treatment of patients with AML that expresses CD33. The combined use of CMA-676 and MDR modifiers may increase the selective cytotoxic effect in multidrug-resistant AML. Leukemia
Introduction
Seventy to 80% of patients with acute myeloid leukemia (AML) achieve complete remission by intensive chemotherapy, but more than 50% of them relapse, often associated with clinical drug resistance. [1] [2] [3] [4] To overcome the resistance, multidrug resistance (MDR) modifiers and new antileukemia agents have been tested clinically. [5] [6] [7] [8] Therapy based on monoclonal antibodies (mAbs) has been used in an attempt to increase the selectivity of cytotoxic agents by conjugating them with a mAb that targets tumor cells. Cytotoxic agents that have been attached to mAbs and tested clinically to date include radioactive isotopes, 9 phytotoxins, 10 enzymes converting prodrugs to active drugs at tumor sites, 11 and standard anticancer agents. 12 Although progress has continued with each of these agents, they all still have drawbacks, and little clinical success has been achieved in leukemia until recently. One of the major limitations of these conjugates is their lack of potency. The cytotoxic ability of conjugates is related to several factors, such as the amount of antigen expression, adequate targeting on tumor-associated antigens, internalization of the conjugate, release of the cytotoxic moiety within the cells, potency of the cytotoxic agent once released intracellularly and its efflux.
CD33, a 67 kDa glycoprotein, is found on the surface of myeloid cells and belongs to the sialoadhesin family of proteins. 13 The exact function of CD33 is not known, but it may be involved in adhesion or cell-to-cell communication. CD33 is expressed on leukemia cells from more than 90% of patients with AML, but is neither expressed on normal hematopoietic stem cells nor on non-myeloid tissues.
14 Therefore, CD33 is a useful target for the development of therapeutic agents in AML. Because CD33 is rapidly internalized after antibody binding, an antibody-cytotoxic agent conjugate can effectively be taken into leukemia cells. In fact, radiolabeled and cytotoxic chemotherapy labeled anti-CD33 antibodies have been developed, including conjugates of 131 I-radioisotope, calicheamicin derivatives, gelonin and ricin. [15] [16] [17] [18] [19] [20] [21] The most encouraging results presented to date have been with CMA-676. CMA-676 is a conjugate of a cytotoxic agent, a calicheamicin derivative, linked to a recombinant humanized antibody (IgG4) directed against the CD33 antigen. Calicheamicin belongs to a family of very potent enediyne antitumor antibiotics that bind to the minor groove of DNA in a sequencespecific manner. [22] [23] [24] Deuterium-labeling experiments showed that the observed double-stranded DNA breaks are caused by the abstraction of specific hydrogen atoms from the deoxyribose rings of DNA by diradical, 25 and the resultant damage to DNA is likely to be the initial step in cell death. A phase II study of CMA-676 in AML is in progress, and a promising result has been reported. 26 However, the effect on the cell cycle distribution has not been reported, and it is not clear whether this DNA damage is related to apoptosis or not. 27, 28 Moreover, the effect on the cells that acquired multidrug resistance has not been elucidated.
Materials and methods

Cell lines
The cell lines used were a human promyelocytic leukemia cell line, HL60; a human chronic myelogenous leukemia cell line, K562 (RIKEN Cell Bank, Tsukuba, Japan); 29 a human promonocytic leukemia cell line, NOMO-1, and its doxorubicinresistant subline, NOMO-1/ADR (kindly provided by Dr M Ogura, Aichi Cancer Center, Nagoya, Japan); 30 31, 32 These cell lines were cultured in RPMI1640 supplemented with l-glutamine (2 mm), antibiotics and 10% fetal calf serum (FCS) (Gibco BRL, Grand island, NY, USA) at 37°C in a humidified 5% CO 2 incubator. Cultures were initiated by seeding 2 × 10 5 cells/ml of fresh medium, and maintained at 2 to 5 × 10 5 cells/ml, adjusting cell concentrations by adding fresh culture medium. Doxorubicin (4 × 10 −7 m) was added every 2 weeks to the culture medium of NOMO-1/ADR cell lines. Vincristine sulfate was added every 2 weeks to the culture medium of NB4/MDR. 31, 32 Flow cytometric analysis for CD33 and CD34 
Flow cytometric analysis for P-glycoprotein, MRP and LRP
For P-glycoprotein (P-gp) analysis, cells underwent a reaction with biotinylated MRK16 (FabЈ) mouse mAb or a subclassmatched control mAb and were then stained with streptavidin-RED670 (Gibco BRL) as previously described. 31, 32 For the analysis of MRP and LRP, cells were first fixed using a mixture of 2% formaldehyde solution and acetone and were then incubated with anti-MRP or anti-LRP mAb (Nitirei, Tokyo, Japan) for 1 h. After being washed, cells were stained with fluorescein isothiocyanate-conjugated rabbit anti-mouse F(abЈ) 2 (Dako Japan, Tokyo, Japan) as reported previously. 33 Ten thousands events were counted using the Epics Elite flow cytometer (Beckman Coulter). The degree of dissociation between the fluorescence intensity of cells that reacted with MRK16, anti-MRP or anti-LRP mAb and that of respective subclass-matched mAb was analyzed by the channel-by-channel subtraction method using the Immuno-4 routine of the Epics cytometer software (Beckman Coulter). The value was defined as the percentage of P-gp, MRP or LRP. 31, 32, 34, 35 The cell count in each channel of the control histogram was subtracted from the cell count in the corresponding channel of the test histogram, and the percent accumulation was calculated from the sum of the difference for all channels.
Reverse-transcription polymerase chain reaction assay for MDR1 expression
Total cellular RNA was extracted according to the acid-guanidinium-phenol-chloroform technique. Complementary DNA (cDNA) was synthesized with a cDNA synthesis kit (Gibco BRL) according to the manufacturer's instructions. 31 In total 40 cycles of polymerase chain reaction (PCR) were performed, using an automatic PCR processor (Perkin Elmer Cetus, Norwalk, CT, USA).
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Figure 1
CD33 and CD34 expression in HL60, NOMO-1, NOMO-1/ADR, NB4, NB4/MDR, NKM-1, K562 and Daudi cells. Vertical and horizontal axes show the amounts of CD33 and CD34 expression, respectively.
Humanized anti-CD33 monoclonal antibody and CMA-676
Humanized anti-CD33 mAb and calicheamicin-conjugated one, CMA-676, were kindly provided by the Wyeth-Ayerst Research Division of American Home Products (Radnor, PA, USA). CMA-676 consists of three essential parts: an antibody, a cytotoxic agent, and a linker. The antibody, humanized IgG4 (hP67.6), targets the CD33 antigen. The cytotoxic agent is N-acetyl-gamma calicheamicin dimethyl hydrazide (NAcgamma calicheamicin DMH), a derivative of calicheamicin antitumor antibiotics, which contains a modified calicheamicin nucleus, a hindered disulfide and a hydrazide. [22] [23] [24] The hydrazide occurs in the conjugate as a hydrazone derivative, which allows for intracellular release via hydrolysis. CMA-676 concentrations were calculated from the concentration of NAc-gamma calicheamicin bound to the antibody. 
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H-thymidine uptake analysis for cell proliferation
Cell cycle distributions
Cell cycle distribution was identified and quantified by flow cytometry with propidium iodide (PI) staining. Cells were collected from culture and washed twice with phosphate-buffered saline (PBS). The centrifuged cell pellet was gently resuspended in 1.0 ml hypotonic fluorochrome solution (PI 50 g/ml in 0.1% sodium citrate plus 0.1% Triton X-100; Sigma, St Louis, MO, USA). The samples were placed in the dark at 4°C overnight before flow cytometric analysis. The orange fluorescence of individual nuclei was measured using the Epics Profile II (Beckman Coulter). 
Dye exclusion test with propidium iodide staining
Morphological analysis by a video-microscopic technique
Cells were plated in a glass-bottomed dish (MatTek Corporation, Ashland, USA) at a concentration of 1 × 10 5 cells in 1.2 ml of medium. The medium was RPMI 1640 containing 10% FCS with 10 ng/ml CMA-676 or the humanized anti-CD33 mAb (hP67.6). After 12-and 24-h incubation at 37°C, cells were observed under an inverted Nomarski microscope (Axiovert 35; Zeiss, Oberkochen, Germany) equipped with a ×100 different interference contrast (DIC) objective lens and a ×2.5 insertion lens. Optical images were detected by using a charge-coupled device (CCD) camera (TI-23P; NEC, Tokyo, Japan), and the contrast of image was enhanced with a highspeed digital image processor (PIP-4000, ADS, Osaka, Japan). The processed image was observed on the monitor screen (14 inch, B/W, Panasonic; Osaka, Japan) and was recorded on a videotape with an S-VHS video cassette recorder (AG-7500; Panasonic). 36 Figures used in this paper were reproduced from still frames in this video record.
DNA fragmentation assay
DNA fragmentation assay was performed as described previously 37 with slight modification. Briefly, cells (2 × 10 6 ) were immersed in cytolysis buffer consisting of 100 l of 100 mm Tris-HCl (pH 7.4), 10 mm EDTA and 0.5% Triton X-100. The mixture was treated with 400 g/ml RNase A (Sigma) and then with 400 g/ml proteinase K (Sigma). DNA was extracted with phenol-chloroform, precipitated with isopropylalcohol, dissolved in 10 l of 10 mm Tris-HCl (pH 7.4) and 1 mm EDTA, and separated in 2% agarose gels. DNA was visualized by staining with ethidium bromide.
Results
CD33 and CD34 expression on cell lines
The expression of CD33 and CD34 on cell lines is shown in Figure 1 . CD33 was expressed on HL60 (99.9%), NOMO-1
Figure 4
Cell cycle distribution of HL60, NOMO-1, NB4 and NKM-1 cells. Cells were incubated with medium alone or with 10 ng/ml or 100 ng/ml of CMA-676 for 48 h.
(99.9%), NOMO-1/ADR (99.9%), NB4 (99.7%), NB4/MDR (99.9%) and NKM-1 (99.9%) cells, but CD34 was not expressed on these cells. In K562 cells, CD33 was partially expressed (62.9%) and CD34 was not expressed. Neither CD33 nor CD34 was expressed on Daudi cells.
Figure 5
Cell cycle distribution of K562 and Daudi. Cells were incubated with medium alone or with 10 ng/ml or 100 ng/ml of CMA-676 for 48 h.
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H-thymidine uptake in HL60 cells
After 12-, 24-and 48-h incubation, 3 H-thymidine uptakes of HL60 cells incubated with 5, 10 and 100 ng/ml of CMA-676 were lower in a dose-dependent manner than that in the control containing no CMA-676 (Figure 2) . The counts per minute measured after 48-h incubation at 5, 10, 100 ng/ml of CMA-676 were 72.9%, 68.7% and 57.6%, respectively, of the control. 3 H-thymidine uptake of cells incubated with non-conjugated anti-CD33 was not significantly different from that of the control.
Cell growth assay by flow cytometry
Viable cell counts were calculated as follows: viable cell counts = (total cell counts) − (PI stained cell counts). The results are shown in Figure 3 . In HL60, NOMO-1, NB4 and NKM-1 cells, CMA-676 suppressed the cell growth at 5, 10 and 100 ng/ml in a dose-dependent manner. In K562 cells, only 100 ng/ml of CMA-676 inhibited the growth. On the other hand, in Daudi cells, CMA-676 did not suppress the growth at all at 100 ng/ml. Although both are meaninglessly high concentrations for clinical use, 1000 and 10 000 ng/ml of CMA-676 suppressed the cell growth of Daudi cells, and the viable cell counts after 48-h incubation were 67% and 18% of the control, respectively.
Cell cycle distribution
Cell cycle distribution patterns after the 48-h incubation with 10 and 100 ng/ml of CMA-676 are shown in Figures 4 and 5 . HL60, NOMO-1 and NB4 cells were arrested at the G2/M phase, and the hypodiploid portions increased. In NKM-1 cells, the effect was less at both concentrations (Figure 4) . In K562 and Daudi cells, a little effect was observed only at 100 ng/ml ( Figure 5 ), and the cell cycle distribution patterns were virtually the same after the 24-h incubation with CMA-676. Although both are meaninglessly high concentrations for clinical use, 1000 ng/ml of CMA-676 arrested partly and 10 000 ng/ml of CMA-676 greatly arrested the cell cycle at the G2/M phase in Daudi cells.
Cell growth of NOMO-1/ADR and NB4/MDR in the absence or presence of an MDR modifier, MS209 or PSC833, by flow cytometry
In the absence of MS209 or PSC833, even 10 000 ng/ml of CMA-676 did not suppress the cell growth of NOMO-1/ADR and NB4/MDR. In the presence of 10 m MS209, CMA-676 recovered the cytotoxic effect and suppressed the cell growth in a dose-dependent manner (Figure 6 ).
In the presence of 10 m PSC833, CMA-676 also recovered the cytotoxic effect and suppressed the cell growth in a dosedependent manner (Figure 6 ).
Cell cycle distribution of NOMO-1/ADR and NB4/MDR in the absence or presence of MS209 or PSC833
The pattern of cell cycle distribution was not changed in either NOMO-1/ADR or NB4/MDR cells with even 10 000 ng/ml of
Figure 6
Cell growth of NOMO-1/ADR and NB4/MDR after the 48-h incubation with 0, 1, 5, 10, 100, 1000 and 10 000 ng/ml of CMA-676 in the absence or presence of 10 m MS209 (a; upper) and in the absence or presence of 10 m PSC833 (b; lower). (᭛) medium alone; () 1 ng/ml of CMA-676; (̆) 5 ng/ml of CMA-676; (×) 10 ng/ml of CMA-676; (*) 100 ng/ml of CMA-676; (b) 1000 ng/ml CMA-676; (͉) 10 000 ng/ml of CMA-676.
CMA-676 after the 48-h incubation (Figures 7, 8 left) . CMA-676 recovered the effect, however, and arrested the cell cycle in both cell lines at the G2/M phase in the presence of 10 m MS209 (Figures 7, 8 right) , and in the presence of 10 m PSC833 (data not shown).
Morphological observation by a video-microscopic technique
The HL60 cells became enlarged after 24-h incubation with 10 ng/ml of CMA-676 compared with the control with the anti-CD33 mAb alone (Figure 9 ). Morphological changes of apoptosis characterized by bleb formation and shrinkage of cells were observed in 15% of the cells.
DNA fragmentation assay in HL60 cells
DNA fragmentation assay was done after incubation for 0, 6, 12, 24, 48 and 72 h with 100 ng/ml of CMA-676 in HL60 cells. DNA ladder formation was not observed (data not shown).
Figure 7
Cell cycle distribution of NOMO-1/ADR cells after the 48-h incubation with 0, 10, 100, 1000 and 10 000 ng/ml CMA-676 in the absence or presence of 10 m MS209.
Discussion
CD33-positive leukemia cell lines, such as HL60, NOMO-1 and NB4 cells, were killed by the exposure to CMA-676, while CD33-negative cell lines, such as Daudi cells, were not. Therefore, CMA-676 acted selectively on CD33-positive cells. Some anticancer drugs, such as paclitaxel, arrest the cell cycle at the G2/M phase and induce cell death. CMA-676 also arrested the cell cycle at the G2/M phase and induced cell death in HL60, NOMO-1 and NB4 cells. K562 cells, which express lower amounts (62.9%) of CD33 and proliferate rapidly, were not influenced by lower concentrations of CMA-676. In Daudi cells, which expressed no CD33, CMA-676 did not suppress the cell growth but slightly arrested the cell cycle at the G2/M phase only at the concentration of 100 ng/ml. Although it is a meaninglessly high concentration for clinical use, 10 000 ng/ml of CMA-676 suppressed the cell growth and arrested the cell cycle at the G2/M phase in Daudi cells. This effect might be explained by the detached calicheamicin from CMA-676 at the highest concentration. On the other hand, the non-conjugated humanized anti-CD33 mAb alone did not act on CD33-positive cells even at 100 ng/ml. Therefore, the cytotoxic effect of CMA-676 must have specifically been derived from calicheamicin.
Complete elimination of blasts from peripheral blood and bone marrow was observed in 20% of chemotherapy-resistant patients enrolled in the phase I trial, with better results achieved in those treated with the higher doses and in those with leukemia with lower MDR efflux. 15 In the phase II trial, 20 of 59 patients (34%) in first relapse achieved a remission (characterized by Ͻ5% blasts in the marrow, 1500/l neutrophils, and platelet transfusion independence prior to any additional post-remission therapy). 26 CMA-676 is a conju-
Figure 8
Cell cycle distribution of NB4/MDR cells after the 48-h incubation with 0, 10, 100, 1000 and 10 000 ng/ml CMA-676 in the absence or presence of 10 m MS209.
gate of a calicheamicin derivative linked to a humanized antibody directed against the CD33 antigen. After internalization of CMA-676 into cells, the calicheamicin derivative is supposed to be released via hydrolysis, and it binds to the minor groove of DNA in a sequence-specific manner. It is not clear whether the DNA damage caused by calicheamicin is related to apoptosis or not. 27, 28 Nicolaou et al 27 reported that DNA damage induced by non-conjugated calicheamicin might lead to apoptotic cell death. One the other hand, Zhao et al 28 reported that calicheamicin might lead to cell death through the exhaustion of NAD+ levels. The video-microscopic technique enabled us to observe cell morphology in a single cell level and to explain this discrepancy. Although 15% of HL60 cells had apoptotic changes, the remaining cells had no apoptotic features. Thus, results of the present study, including the DNA fragmentation assay and the light scatter properties in flow cytometry, suggested that CMA-676 mainly induced nonapoptotic cell death. Here, we did not compare calicheamicin with CMA-676, because calicheamicin was not available. However, the cytotoxic mechanism of calicheamicin would presumably be the same as that of CMA-676 except for the internalization via CD33 antigen.
CMA-676 showed no effect on multidrug-resistant sublines even if they expressed sufficient amounts of CD33. MDR is a phenomenon in which malignant cells develop cross-resistance to a variety of unrelated cytotoxic drugs. Mdr-1-associated P-gp is a membrane glycoprotein that actively pumps the cytotoxic agent out from the cells and decreases intracellular drug accumulation. 38, 39 Therefore, calicheamicin derivatives could also be pumped out from the cells. This hypothesis was confirmed by a combined use of CMA-676 and MDR modifiers in resistant sublines. MS209 is a novel quinoline compound that can overcome MDR both in vitro and in vivo. 40 
Figure 9
Morphological observation of HL60 cells by a videomicroscope. HL60 cells were incubated with 10 ng/ml of CMA-676 for 24 h.
PSC 833 is another potent MDR-reversing drug that is a nonimmunosuppressive analogue of cyclosporine. 41 MS209 and PSC833 recovered the cytotoxic effect of CMA-676 in P-gpexpressing sublines. Because CD33 is rapidly internalized following antibody binding, calicheamicin can effectively be taken into cells. Although it is not known whether calicheamicin is pumped out by P-gp at present, our experiments suggested that intracellularly released calicheamicin was probably pumped out via P-gp. Additionally, in a phase I study of CMA-676, a high rate of clinical response was observed in leukemias characterized by low dye efflux in vitro. 15 In CMA-676, MDR modifiers theoretically work only on intracellularly incorporated calicheamicin in CD33-positive cells. Therefore, the combined use of CMA-676 and MDR modifiers may be an ideal therapeutic approach on P-gp-related resistant tumors, assuming that the hematologic and non-hematologic toxicities are not worsened.
Phase II studies of CMA-676 are now in progress. This new agent will bring a considerable therapeutic benefit for patients with CD33-positive AML. However, in relapsed or refractory AML which expressed P-gp, the combined use of MDR modifiers has the potential to produce an improved therapeutic ratio. Clinical studies with MDR modifiers will be required to determine whether an increase in efficacy occurs, and whether any increase in efficacy is accompanied by worsening of associated adverse events.
